Enveric Biosciences, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 25, 2024. This is an annual report, not a quarterly filing. Enveric is a pre-revenue biotechnology company developing psychedelic-inspired therapeutics. Its lead programs, EB-002 and EB-003, remained in preclinical development at year-end.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $7.25 million | $8.03 million |
| General and administrative expense | $8.85 million | $11.61 million |
| Total operating expenses / operating loss | $16.45 million | $27.42 million |
| Net loss | $17.29 million | $18.47 million |
| Operating cash used | $14.09 million | $17.15 million |
| Cash at year-end | $2.29 million | $17.72 million |
| Working capital at year-end | $1.24 million | Not clearly stated in the filing text |
| Total assets | $4.30 million | $19.55 million |
| Shareholders’ equity | $1.96 million | $14.67 million |
Operating expenses fell about 40%, largely because 2022 included $7.45 million of impairment charges; excluding that item, 2023 operating expenses were lower by about $3.51 million. R&D expense declined about 10%, as lower payroll and lab costs more than offset higher CRO spending. Net loss narrowed about 6%. No revenue means revenue-based margins are not meaningful.
Cash declined by $15.44 million during 2023. Financing cash flow was negative $1.34 million, principally reflecting the $1.05 million redemption of Akos Series A preferred stock and $0.29 million of offering costs. The company reported no revenue and relied principally on equity financing. The filing text does not identify material conventional borrowings; reported liabilities include payables, accruals, and warrant or investment-option liabilities.
Material changes and notable items
- In May 2023, Enveric reduced its workforce by approximately 35% and ended contracts with seven consultants associated with the Akos cannabinoid spin-off. It reported $1.00 million of restructuring costs incurred, with $0.30 million accrued at year-end.
- Enveric redeemed all Akos Series A preferred stock in May 2023 for approximately $1.05 million. The planned Akos spin-off was not completed.
- In December 2023, warrant holders agreed to exercise existing warrants and investment options at a reduced price in exchange for new warrants. The company recorded $1.85 million of inducement expense. Proceeds of $1.82 million were received in January 2024 and recorded as a year-end subscription receivable.
- After year-end, the company reported approximately $2.7 million of gross proceeds from warrant exercises in February 2024 and $2.32 million of net proceeds from Canaccord at-the-market sales. Management also described additional equity-financing channels, subject to contractual and securities-law limitations.
- For 2023, the company recorded no impairment of intangible assets or goodwill; $7.45 million was impaired in 2022.
Outlook, risks, and contingencies
- Going concern: The auditor included a going-concern explanatory paragraph, and management concluded substantial doubt exists about the company’s ability to continue for one year after issuance of the financial statements. Management said year-end cash plus first-quarter 2024 funding was expected to support current operations into the fourth quarter of 2024, but not beyond. Additional financing is not assured; failure to obtain it could require further cuts, delays, or discontinuation of activities.
- Development outlook: EB-002 was being advanced toward a planned first-in-human study in Australia, subject to preclinical work and ethics/regulatory approvals. EB-003 was selected as the EVM301 lead candidate in December 2023; the next stated step was formal preclinical studies supporting a future IND filing. No product-candidate revenue or approval guidance was provided.
- Clinical and regulatory risk: Candidates are early-stage, and success depends on costly, uncertain preclinical and clinical testing and regulatory approvals. Psychedelic-derived compounds face controlled-substance requirements; the filing notes that key scheduling and regulatory questions remain unresolved.
- Capital and listing risks: Nasdaq notified Enveric it fell below the $2.5 million stockholders’ equity requirement based on September 2023 results. The company received an extension to May 20, 2024 and said it must evidence compliance with its June 30, 2024 periodic report. Failure could lead to delisting. Financing may dilute existing shareholders; certain warrant inducement terms also restricted variable-rate transactions.
- Financial reporting controls: Management concluded internal control over financial reporting and disclosure controls were ineffective at year-end due to material weaknesses, including inadequate documentation and insufficient segregation of duties. Remediation was in progress, not complete.
- Other exposures: Management cited inflation-related labor and materials costs, dependence on external CROs and vendors, intellectual-property protection, and a Canadian drug license scheduled to expire December 31, 2024. The company reported no pending litigation believed to have a material adverse effect.
Most important facts for investors to verify
- Available cash, subsequent financing proceeds, contractual restrictions on financing, and the realistic cash runway beyond the company’s stated fourth-quarter 2024 estimate.
- Whether Nasdaq listing-equity compliance was achieved by the applicable deadlines and whether the shares remain listed.
- Progress and regulatory status of EB-002 and EB-003, including the timing and funding required to begin clinical studies.
- Share-count and dilution effects of warrant exercises, inducement warrants, ATM sales, and the Lincoln Park equity line.
- Remediation of the disclosed material weaknesses and any subsequent changes in controls.
- Clarification of product-candidate naming: the filing refers to EB-002 in several sections but identifies the lead EVM201 candidate as EB-373 in other sections, and also contains EB-003/EBV003 references.